Literature DB >> 17388607

Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.

Guoyu Pan1, William F Elmquist.   

Abstract

Mitoxantrone (MXR) is a prototypical substrate for the ABCG2 (bcrp1) efflux transporter and is often used as a positive control in bcrp-mediated transport studies. This study examined processes involved in the cellular accumulation and directional transport of MXR using an in vitro wild-type (WT) and bcrp1-transfected (bcrp1) MDCKII cell model. Compared to 37 degrees C, incubation at 4 degrees C increased MXR accumulation in bcrp1 cells and unexpectedly decreased MXR accumulation in WT MDCKII cells. [3H]-MXR accumulation was concentration dependent in both WT and bcrp1 cells, exhibiting the characteristics of saturable active influx. At tracer concentrations, there was no difference in MXR directional flux between WT and bcrp1 MDCKII cell monolayers, and the A-to-B (apical-to-basolateral) flux was greater than the B-to-A flux in both cell types. However at higher concentration (20 microM), [3H]-MXR directional flux from A to B decreased and B to A increased, revealing the expected efflux process. Therefore, the orientation of the MXR directional flux process is concentration dependent and only at higher concentrations could the difference between WT and bcrp1 MDCKII cells be distinguished. Taken together, these data show that there is a saturable influx transport system on the apical membrane MDCKII cells that is responsible for the active influx of MXR. This is the first report of an active influx transport system for MXR. The expression of the putative MXR influx transporter in selected cell types could lead to misleading results in drug transport assays that screen for bcrp activity. Moreover, the downregulation of the influx transport system could be a heretofore unrecognized mechanism of MXR resistance in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388607     DOI: 10.1021/mp060083b

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

1.  Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells.

Authors:  Guoyu Pan; Tate N Winter; John C Roberts; Carolyn A Fairbanks; William F Elmquist
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

2.  Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

Authors:  Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 3.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

4.  Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).

Authors:  Durga Kalyani Paturi; Deep Kwatra; Hari Krishna Ananthula; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2009-09-25       Impact factor: 5.875

Review 5.  Altered Expression of Transporters, its Potential Mechanisms and Influences in the Liver of Rodent Models Associated with Diabetes Mellitus and Obesity.

Authors:  Leilei Ma; Lei He; Le Wang; Li Li; Xuena Lin; Guoyu Pan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-06       Impact factor: 2.441

6.  Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.

Authors:  Joe Bentz; Harma Ellens
Journal:  Methods Mol Biol       Date:  2021

7.  Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms.

Authors:  Yimao Zhang; Mrudula Pullambhatla; John Laterra; Martin G Pomper
Journal:  Mol Imaging       Date:  2012 Nov-Dec       Impact factor: 4.488

8.  Investigation of Enantioselective Membrane Permeability of α-Lipoic Acid in Caco-2 and MDCKII Cell.

Authors:  Ryota Uchida; Hinako Okamoto; Naoko Ikuta; Keiji Terao; Takashi Hirota
Journal:  Int J Mol Sci       Date:  2016-01-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.